Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126789 · ClinicalTrials.gov registry record · Phase 3
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
A Phase 3 study, sponsored by ZARS Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT00126789 is a Phase 3 study that was terminated before completion, run by ZARS Pharma. The registered enrollment target is 24 participants.
The verdict
NCT00126789, a Phase 3 study, was terminated before completion, sponsored by ZARS Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.
Interventions
- DRUG Fentanyl Transdermal Matrix Patch ZR-02-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126789
The ClinicalTrials.gov registry entry for NCT00126789 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fentanyl Transdermal Matrix Patch ZR-02-01 is the first listed.
NCT00126789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126789 about?
NCT00126789 is a clinical study titled "Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain". The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.
What is the current status of trial NCT00126789?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2005-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00126789?
The interventions under investigation include: Fentanyl Transdermal Matrix Patch ZR-02-01 (DRUG).
Who is sponsoring clinical trial NCT00126789?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.